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Abstract 
Background: Anemia is considered a negative prognostic risk factor for survival in patients with myelofibrosis. Most 
patients with myelofibrosis are anemic, and 35–54 % present with anemia at diagnosis. Ruxolitinib, a potent inhibitor 
of Janus kinase (JAK) 1 and JAK2, was associated with an overall survival benefit and improvements in splenomegaly 
and patient‑reported outcomes in patients with myelofibrosis in the two phase 3 COMFORT studies. Consistent with 
the ruxolitinib mechanism of action, anemia was a frequently reported adverse event. In clinical practice, anemia is 
sometimes managed with erythropoiesis‑stimulating agents (ESAs). This post hoc analysis evaluated the safety and 
efficacy of concomitant ruxolitinib and ESA administration in patients enrolled in COMFORT‑II, an open‑label, phase 
3 study comparing the efficacy and safety of ruxolitinib with best available therapy for treatment of myelofibrosis. 
Patients were randomized (2:1) to receive ruxolitinib 15 or 20 mg twice daily or best available therapy. Spleen volume 
was assessed by magnetic resonance imaging or computed tomography scan.
Results: Thirteen of 146 ruxolitinib‑treated patients had concomitant ESA administration (+ESA). The median expo‑
sure to ruxolitinib was 114 weeks in the +ESA group and 111 weeks in the overall ruxolitinib arm; the median ruxoli‑
tinib dose intensity was 33 mg/day for each group. Six weeks before the first ESA administration, 10 of the 13 patients 
had grade 3/4 hemoglobin abnormalities. These had improved to grade 2 in 7 of the 13 patients by 6 weeks after the 
first ESA administration. The rate of packed red blood cell transfusions per month within 12 weeks before and after 
first ESA administration remained the same in 1 patient, decreased in 2 patients, and increased in 3 patients; 7 patients 
remained transfusion independent. Reductions in splenomegaly were observed in 69 % of evaluable patients (9/13) 
following first ESA administration.
Conclusions: Concomitant use of an ESA with ruxolitinib was well tolerated and did not affect the efficacy of 
ruxolitinib. Further investigations evaluating the effects of ESAs to alleviate anemia in ruxolitinib‑treated patients are 
warranted (ClinicalTrials.gov identifier, NCT00934544; July 6, 2009).
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rate in transfusion-dependent patients, suggest that ane-
mia in patients taking ruxolitinib is generally not a long-
term safety concern.
In COMFORT-II, anemia was primarily managed with 
packed red blood cell (PRBC) transfusions. In clinical 
practice, anemia can also be managed with erythropoie-
sis-stimulating agents (ESAs; e.g., darbepoetin alfa, epo-
etin alfa) [15], which improve hemoglobin levels and may 
eliminate the need for transfusions [15]. In patients with 
MF, ESAs can be ineffective, especially if patients are 
transfusion dependent or have elevated erythropoietin 
levels [16–18]. In COMFORT-II, ESA use was discour-
aged (although not prohibited) because ESAs can activate 
the JAK pathway, potentially resulting in increased spleen 
size and thereby confounding efficacy analyses of spleen 
response [15, 19]. A small number of patients (13/146), 
however, received both an ESA and ruxolitinib. This 
report evaluates the safety and efficacy of concomitant 
ruxolitinib and ESA administration in these 13 patients.
Results and discussion
To aid in the management of anemia, ESAs were admin-
istered to 13 of 146 ruxolitinib-treated patients (9  %; 
+ESA group; darbepoetin alfa, n = 3; epoetin alfa, n = 9; 
unspecified epoetin, n  =  1). ESA schedules varied and 
doses ranged from 10,000 to 40,000 units for epoetin alfa; 
40–300  μg, 150–300  μg, and 500  μg in the 3 patients 
receiving darbepoetin alfa; and 10,000–20,000  IU for 
unspecified epoetin. The median exposure to ruxolitinib 
was similar between the +ESA group (114  weeks) and 
the overall ruxolitinib arm (111 weeks), and the median 
ruxolitinib dose intensity was the same for both groups 
(33 mg/day). In the +ESA group, 11 patients (84.6 %) had 
dose reductions or interruptions of ruxolitinib—a rate 
that was similar to that in the overall study population at 
the time of the primary analysis (71.2 %). At study base-
line, and prior to treatment with ruxolitinib or an ESA, 
patients who received concomitant ESAs presented with 
low hemoglobin levels [median hemoglobin level, 92 g/L 
(range 83–144) vs 106.0 g/L (range 65–162) in the ruxoli-
tinib arm; median reticulocyte count, 138 × 109/L (range 
96.0–141.0) vs 121.85 × 109/L (range 9.3–283.2), respec-
tively; Table 1] and showed no signs of renal impairment 
[median creatinine level, 70.2 µmol/L (range 55.0–134.7) 
vs 75.25  µmol/L (range 38.8–172.5)], indicating anemia 
was not due to a combination of chronic kidney disease 
and erythropoietin deficiency. Comparative statistics 
between the overall ruxolitinib arm and +ESA group 
were not possible due to the small sample size of the 
+ESA group.
Background
Myelofibrosis (MF) is a clonal neoplastic disease char-
acterized by bone marrow fibrosis, splenomegaly, and 
debilitating constitutional symptoms (fever, weight loss, 
night sweats) [1–4]. Dysregulation of the Janus kinase 
(JAK) pathway is considered to be the primary mecha-
nism responsible for the pathophysiology of MF [5], 
which results in clonal myeloproliferation associated 
with bone marrow fibrosis, extramedullary hematopoie-
sis, and abnormal cytokine expression [6]. Progressive 
bone marrow fibrosis leads to several cytopenias, par-
ticularly thrombocytopenia and anemia [7]. MF-asso-
ciated anemia is multifactorial [8] and is considered a 
negative prognostic risk factor for survival [1]. Between 
35 and 54 % of patients present with anemia at diagno-
sis, with the proportion increasing to 47–64  % after 
1  year or more from MF diagnosis [8–10]. Ruxolitinib 
is a potent JAK1 and JAK2 inhibitor that has demon-
strated rapid and durable reductions in splenomegaly 
and improved symptoms and quality of life measures 
in the two phase 3 Controlled Myelofibrosis Study with 
Oral JAK Inhibitor Treatment (COMFORT) trials [11, 
12]. Ruxolitinib-treated patients experienced prolonged 
survival compared with placebo (COMFORT-I) [11, 13] 
and best available therapy (BAT; COMFORT-II) [12], 
suggesting an overall survival benefit associated with 
ruxolitinib treatment. Consistent with the mechanism of 
action of ruxolitinib and the pathophysiology of MF, ane-
mia (hemoglobin level <100 g/L) was one of the most fre-
quently reported adverse events (AEs) but was generally 
manageable; only 2 of 146 patients (1 %) in COMFORT-II 
discontinued due to anemia after approximately 3  years 
of treatment (median follow-up, 151 weeks) [14].
Findings from both COMFORT studies suggest that 
low hemoglobin levels may be an initial concern with 
ruxolitinib but that hemoglobin levels increase with 
longer-term treatment. In COMFORT-II, ruxolitinib-
treated patients experienced an initial decrease in 
mean hemoglobin levels over the first 12  weeks, but 
levels recovered to levels similar to those in the BAT 
arm and remained greater than 100  g/L from week 24 
onward (>151  weeks) [14]. These data mirrored those 
from COMFORT-I in which mean hemoglobin levels 
in the ruxolitinib arm reached a nadir at approximately 
8–12 weeks and recovered to a new steady state by week 
24, independent of transfusions or dose reduction [3, 
11]. Additionally, long-term follow-up of COMFORT-I 
showed that the incidence of new-onset grade 3/4 ane-
mia decreased with longer-term therapy [13]. These data, 
in concert with the observed reduction in transfusion 
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In the 13 patients who received concomitant rux-
olitinib and ESA, the worst hemoglobin value within 
12 weeks of ESA administration improved in 3 patients, 
worsened in 2 patients, and did not change in 7 patients, 
compared with their worst pre-ESA study assessments; 
data were not available for 1 patient (Table 1). In patients 
with assessments at 12 weeks after the first ESA adminis-
tration (n = 8), 6 patients had increases (median increase 
7  g/L; range 5–57  g/L) and 2 patients had decreases in 
hemoglobin levels; 5 patients had no data available. The 
rate of PRBC transfusions per month within the 12 weeks 
before and after first ESA use (mean transfusion rates, 
0.8 and 1.3, respectively) did not change for 1 patient, 
decreased for 2 patients, and increased for 3 patients 
(Table 1). Seven patients were transfusion independent at 
baseline and remained transfusion independent through-
out this analysis (Table 1). Most patients (85 %) did not 
have any substantial change in reticulocyte counts within 
12 weeks after ESA administration (Table 1).
The AEs reported in the +ESA group (n  =  13) were 
similar to those previously reported in the overall 
ruxolitinib arm (n  =  146) [12]. Six weeks prior to the 
first ESA administration, 10 of the 13 patients (77 %) had 
grade 3/4 hemoglobin abnormalities; 6 weeks after ESA 
use, most patients’ hemoglobin abnormalities improved 
to grade 2 [7/13 (54  %)], suggesting the concomitant 
use of an ESA and ruxolitinib was beneficial in some 
patients. Overall, serious AEs were reported for 8 of the 
13 patients in the +ESA group (Table 2). Three patients 
experienced serious AEs (SAEs) prior to the first ESA 
administration, 2 experienced SAEs before and after the 
first administration, and 7 experienced SAEs after the 
first administration. One patient experienced a pulmo-
nary embolism, potentially due to ESA use. Three events 
in 2 patients were possibly related to ruxolitinib: 1 patient 
experienced general health deterioration (grade 3) and 
respiratory tract infection (grade 4), and 1 patient expe-
rienced anemia (grade 3). There were 2 thromboembolic 
events; 1 patient had a pulmonary embolism (mentioned 
above), and a second patient had a grade 2 splenic infarct 
that occurred prior to ESA administration and was not 
suspected to be related to treatment.
Table 1 Transfusion rates, hemoglobin levels, reticulocyte counts, and changes in spleen volume before and after ESA
BL baseline, ESA erythropoiesis-stimulating agent, max maximum, min minimum, NA no assessment available, PRBC packed red blood cell, pt patient
a Change in PRBC transfusions 12 weeks before the first administration of ESA
b Change in PRBC transfusions 12 weeks after the first administration of ESA
c Change in the worst hemoglobin value and the highest reticulocyte count measured 6 weeks prior to the first administration of ESA
d Change in the worst hemoglobin value and the highest reticulocyte count measured 12 weeks after the first administration of ESA
e Percentage change in spleen volume from baseline to the last assessment prior to the first administration of ESA
f Percentage change in spleen volume from baseline to the first assessment after the first administration of ESA
Pt Transfusion rate, units PRBC/
month
Hemoglobin value, g/L Reticulocyte count, ×109/L Spleen volume, L












BL Change from BL (%)
Before ESAe After ESAf
1 0 2.9 2.9 106 62 69 116.9 42.5 41 2.48 −13 −20
2 0.7 2.2 10.7 99 75 60 144.9 110 114.3 3.47 −22 NA
3 0.7 1.8 0.7 100 62 NA 162.1 90 NA 2.29 −29 NA
4 0 0 0.7 121 68 66 98.1 61 64 1.79 −8 −15
5 2.9 2.9 0 90 74 40 96 167 120.3 3.43 +11 −3
6 1.4 0.7 2.2 83 67 73 81.1 74 NA 3.07 −3 NA
7 0 0 0 144 78 88 156.4 39 96.1 3.04 −36 −50
8 0 0 0 93 81 80 138 82 73.4 5.24 −45 −34
9 0 0 0 90 76 78 66.9 42 42.5 2.53 −65 −67
10 0 0 0 86 74 91 92.1 49 75.7 0.46 −54 −58
11 0 0 0 92 76 73 141 106 74.9 3.16 −13 −20
12 0 0 0 90 87 84 283.2 247 205.2 2.07 −22 NA
13 0 0 0 89 84 86 57.1 32 34.6 2.15 −29 −44
Median 0.7 2 1.45 92 75 78 138.0 78 52.5 2.53 −22 −34
Min 0.0 0.0 0.0 83.0 62.0 60.0 96.0 32.0 41.0 0.46 −65.0 −67.0
Max 2.9 2.9 10.7 144.0 87.0 91.0 141.0 247.0 64.0 5.24 11.0 −3.0
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The use of an ESA did not appear to affect the efficacy 
of ruxolitinib with regard to splenomegaly. Twelve of the 
13 patients (92  %) had spleen volume reductions from 
baseline with ruxolitinib treatment prior to ESA admin-
istration (Table 1). All 8 of 12 evaluable patients had sus-
tained reductions after ESA administration, with 7 of 
these 8 patients showing a greater reduction in spleen 
volume after ESA use. Additionally, 1 patient experi-
enced a reduction in spleen volume from baseline after 
ESA administration indicating a response to ruxolitinib 
(Table 1). These effects on spleen volume were not asso-
ciated with an increased ruxolitinib dose; in fact, for 
most patients, the total daily dose of ruxolitinib remained 
the same or was lower after ESA administration.
As might be expected from what is known about JAK/
STAT signaling [20], ruxolitinib-treated patients had 
higher median levels of erythropoietin than patients 
treated with BAT. The median levels of erythropoietin 
at baseline were similar in both the ruxolitinib (8.6  pg/
mL, 95  % CI 7–13  pg/mL) and BAT (11.0  pg/mL, 95  % 
CI 7–21 pg/mL) arms. There was an initial rapid increase 
in erythropoietin levels in ruxolitinib-treated patients 
(150.0 % change from baseline at week 4), but no change 
was observed with BAT. Ruxolitinib-treated patients had 
higher median levels of erythropoietin than BAT-treated 
patients at week 24 (ruxolitinib, 36.0  pg/mL, 95  % CI 
19–77  pg/mL; BAT, 8.7  pg/mL, 95  % CI 7–29  pg/mL) 
and even higher levels at week 48 [54.0 pg/mL, 95 % CI 
31–98  pg/mL (216.3  % change) vs 26.0  pg/mL, 95  % CI 
16–72 pg/mL (77.0 % change), respectively]. One expla-
nation for the difference in erythropoietin levels between 
patients treated with ruxolitinib and BAT lies in the 
mode of action of both erythropoietin and ruxolitinib. 
Erythropoietin is the main regulator of erythropoiesis. 
Direct binding of erythropoietin to its receptor acti-
vates JAK2, which initiates signal transduction pathways 
that lead to the proliferation and terminal differentia-
tion of erythroid precursor cells [20]. In patients receiv-
ing ruxolitinib, inhibition of JAK2 signaling may lead to 
impaired erythropoiesis and, potentially, anemia. The 
resulting decrease in the body’s oxygen levels causes cir-
culating erythropoietin levels to increase up to 1000-fold 
in an attempt to boost the blood’s oxygen-carrying capac-
ity by increasing red blood cell (and thus hemoglobin) 
concentration. Since ESAs share the same mechanism 
of action as endogenous erythropoietin, one might not 
expect treatment with an ESA to benefit patients with 
MF. Interestingly, it is the serum half-life of erythropoi-
etin rather than the concentration that is mainly respon-
sible for increased RBC concentrations, and recombinant 
ESAs currently in use have a prolonged terminal half-life 
compared with endogenous erythropoietin [20]. The pro-
longed half-life of ESAs in comparison to the relatively 
short half-life of ruxolitinib may be what aided some 
COMFORT-II patients in obtaining the clinical benefits 
observed in the treatment of anemia [20].
Despite these observed clinical benefits, previous stud-
ies have suggested that ESAs have limited activity in 
patients with MF with transfusion dependency, marked 
splenomegaly, serum erythropoietin level >125 U/L, or 
JAK2 V617F homozygosity [16, 18]. One study evaluat-
ing the use of darbepoetin alfa in patients with MF, mye-
loid metaplasia, and anemia found that no patient with 
Table 2 Serious adverse events regardless of  relationship 
to study drug
ESA erythropoiesis-stimulating agent, NA not applicable (no SAE reported), pt 
patient, SAE serious adverse event
a Suspected by the investigator to have a relationship to the study drug
b Common Toxicity Criteria Grade 3 anemia
Preferred term
Pt Before ESA After ESA
1 Cholesteatoma
2 Respiratory tract infection General physical deteriorationa
Respiratory tract infectiona
Renal failure, acute




6 Pulmonary arterial hypertension Ascites
Anemiab Encephalopathy
Varices esophageal Enterococcal sepsis
Upper gastrointestinal hemorrhage
8 NA Herpes zoster
Pulmonary embolism
Cardiac failure















10 NA Traumatic fracture
13 NA Gastroenteritis
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adequate erythropoietin levels (≈2–5 pM) responded to 
treatment [17]. Another study found that patients with 
primary MF (N = 43, Mayo Clinic, Rochester, MN) had a 
low overall response rate to treatment with an ESA (23 %) 
and that the response rate was not correlated with base-
line serum erythropoietin level in any of the 43 patients 
(including transfusion-independent patients, n = 27), nor 
with primary MF-specific treatment history, use of con-
current cytoreductive therapy, cytogenetic findings, or 
JAK2 V617F presence [16]. In addition to these findings, 
safety concerns such as the association of leukemic trans-
formation with ESA use [16] have led investigators to rec-
ommend against ESA administration in patients with MF 
who are transfusion dependent or have a baseline hemo-
globin ≥100 g/L [16, 17]. It can be noted that whereas the 
pathogenesis of MF-related anemia is complex, involving 
factors such as aberrant erythropoiesis and persistent 
low-grade hemolysis, ruxolitinib-associated anemia is 
self-limiting and dose dependent [21]; potential differ-
ences in the ability of an ESA to counteract MF-related 
and JAK inhibitor-mediated anemia may lie in this dis-
tinction [8, 11, 12, 22, 23]. Although the efficacy of an 
ESA to control JAK inhibitor-induced anemia in patients 
with MF is yet unknown, this analysis suggests that ESA 
use in this patient population is safe and could become a 
tool in helping patients achieve control of JAK inhibitor-
induced anemia.
Conclusions
In this report, the data suggest that concomitant use of 
an ESA with ruxolitinib is safe and does not affect the 
efficacy of ruxolitinib. However, the study is limited by 
the small number of patients analyzed and no definitive 
recommendations can be made at this time regarding the 
use of ESAs in the management of anemia in ruxolitinib-
treated patients. Further investigations of ESAs in com-
bination with ruxolitinib in this patient population are 
needed to help guide clinical decisions.
Methods
COMFORT-II (ClinicalTrials.gov identifier, 
NCT00934544) is a randomized, open-label, multicenter 
phase 3 study comparing the safety and efficacy of rux-
olitinib with BAT for the treatment of MF [12]. Patients 
with primary MF, post-polycythemia vera MF, or post-
essential thrombocythemia MF classified as intermedi-
ate-2 or high risk by International Prognostic Scoring 
System criteria [1] were randomized 2:1 to receive ruxoli-
tinib (15 or 20 mg twice daily, based on baseline platelet 
count [100–200 or >200 ×  109/L, respectively]) or BAT 
[1, 12]. Further study design details have been presented 
previously [12]. To prevent confounding efficacy analy-
ses of spleen response, ESA use was discouraged but not 
prohibited [12]. ESAs were administered per investiga-
tor discretion based on joint recommendations from the 
American Society of Hematology and American Society 
of Clinical Oncology [15]. Transfusion rates were calcu-
lated as the PRBC units transfused per month within the 
12  weeks before and after the first ESA administration. 
Spleen volumes were assessed by magnetic resonance 
imaging or computed tomography scan. Assessments 
were completed every 12  weeks in the core study until 
the primary endpoint was reached; responders were 
followed at 12-week intervals thereafter (data cutoff, 1 
March 2012).
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